Trial Profile
Remicade [infliximab] Treatment Registry in Rheumatoid Arthritis I.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 24 Feb 2010 Actual patient number (33) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.